Journal of Ophthalmology (Jan 2014)
Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma
- Ahmad M. Mansour,
- J. Fernando Arevalo,
- Eman Al Kahtani,
- Hernando Zegarra,
- Emad Abboud,
- Rajiv Anand,
- Hamid Ahmadieh,
- Robert A. Sisk,
- Salman Mirza,
- Samuray Tuncer,
- Amparo Navea Tejerina,
- Jorge Mataix,
- Francisco J. Ascaso,
- Jose S. Pulido,
- Rainer Guthoff,
- Winfried Goebel,
- Young Jung Roh,
- Alay S. Banker,
- Ronald C. Gentile,
- Isabel Alonso Martinez,
- Rodney Morris,
- Neeraj Panday,
- Park Jung Min,
- Emilie Mercé,
- Timothy Y. Y. Lai,
- Vicky Massoud,
- Nicola G. Ghazi
Affiliations
- Ahmad M. Mansour
- Departments of Ophthalmology, American University of Beirut, Rafic Hariri University Hospital, P.O. Box 113-6044, Beirut, Lebanon
- J. Fernando Arevalo
- Vitreoretinal Division, The King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
- Eman Al Kahtani
- Vitreoretinal Division, The King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
- Hernando Zegarra
- Retina Associates of Cleveland, 3401 Enterprise Parkway, Suite 300, Beachwood, OH 44122, USA
- Emad Abboud
- Vitreoretinal Division, The King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
- Rajiv Anand
- Texas Retina Associates, University of Texas Southwestern Medical Center, Dallas, TX 75231, USA
- Hamid Ahmadieh
- Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Labbafinejad Medical Center, Tehran, Iran
- Robert A. Sisk
- Cincinnati Eye Institute, Cincinnati, OH 45212, USA
- Salman Mirza
- Birmingham Midland Eye Centre, Dudley Road, Birmingham B187QH, UK
- Samuray Tuncer
- Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Sergul Sokak Sarali Sitesi, A2 3 Gayrettepe, 34349 Istanbul, Turkey
- Amparo Navea Tejerina
- Fundación Oftalmológica del Mediterráneo, 46015 Valencia, Spain
- Jorge Mataix
- Fundación Oftalmológica del Mediterráneo, 46015 Valencia, Spain
- Francisco J. Ascaso
- Department of Ophthalmology, “Lozano Blesa” University Clinic Hospital, School of Medicine, University of Zaragoza, 50001 Zaragoza, Spain
- Jose S. Pulido
- Mayo Clinic, 200 1st Avenue South West Rochester, Minnesota, MN 55902, USA
- Rainer Guthoff
- University-Eye Hospital Duesseldorf, Moorenstraße 5, 40225 Duesseldorf, Germany
- Winfried Goebel
- Department of Ophthalmology, University of Wuerzburg, 97080 Wuerzburg, Germany
- Young Jung Roh
- Department of Ophthalmology, St. Mary’s Hospital, Catholic University of Korea, Seoul 137-701, Republic of Korea
- Alay S. Banker
- Banker’s Retina Clinic and Laser Centre, 5 Subhash Society, Behind Ishvar Bhuvan, Ahmedabad, Gujarat 380009, India
- Ronald C. Gentile
- Department of Ophthalmology, New York Eye and Ear Infirmary, New York, NY 10014, USA
- Isabel Alonso Martinez
- Martinez Center, Avenida María Guerrero 144, Leganés Norte, 28919 Madrid, Spain
- Rodney Morris
- Department of Retina and Vitreous, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Avinashi Road, Coimbatore, Tamil Nadu 641014, India
- Neeraj Panday
- MM Joshi Eye Institute, Gokul Road, Hosur, Hubli, Karnataka 580021, India
- Park Jung Min
- Maryknoll Medical Center, 4-12 Daecheong-dong, Jung-gu, Busan 600-730, Republic of Korea
- Emilie Mercé
- Service d’Ophtalmologie, CHU Dupuytren, 87042 Limoges, France
- Timothy Y. Y. Lai
- Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong
- Vicky Massoud
- Departments of Ophthalmology, American University of Beirut, Rafic Hariri University Hospital, P.O. Box 113-6044, Beirut, Lebanon
- Nicola G. Ghazi
- Vitreoretinal Division, The King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
- DOI
- https://doi.org/10.1155/2014/210458
- Journal volume & issue
-
Vol. 2014
Abstract
We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n=15; P=0.001), 105.3 microns at 1 year (n=10; P=0.03), and 157.6 microns at 2 years (n=7; P=0.08). BCVA improved by 3.3 lines at 6 months after therapy (n=26; P<0.001), 2.8 lines (n=20; P=0.01) at 1 year, and 3.1 lines (n=13; P=0.049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.
